BNTX - Sell-siders like BioNTech in premarket analyst action November, 04 2019 08:41 AM BioNTech SE Allogene Therapeutics (NASDAQ:ALLO) initiated with Buy rating and $36 (24% upside) price target at Canaccord Genuity.More news on: Allogene Therapeutics, Inc., BioNTech SE, TCR2 Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...